What is Enliven Therapeutics Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Enliven Therapeutics's interest expense for the
three
months ended in Mar. 2024 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Enliven Therapeutics's Operating Income for the
three
months ended in Mar. 2024 was $ -25.99 Mil. Enliven Therapeutics's Interest Expense for the
three
months ended in Mar. 2024 was $ 0.00 Mil.
Enliven Therapeutics has no long-term debt (1).
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Enliven Therapeutics Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enliven Therapeutics (NAS:ELVN) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Enliven Therapeutics's Interest Expense for the
three
months ended in Mar. 2024 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Mar. 2024 was $-25.99 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2024 was $0.00 Mil.
Enliven Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as
| Enliven Therapeutics had no long-term debt (1). |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Enliven Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.
Enliven Therapeutics (Enliven Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
6200 Lookout Road, Boulder, CO, USA, 80301
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially best-in-class or first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases.
Executives
| Anish Patel |
officer: Chief Operating Officer |
C/O ENLIVEN THERAPEUTICS INC, 6200 LOOKOUT ROAD, BOULDER CO 80301 |
| Benjamin Hohl |
officer: Chief Financial Officer |
6200 LOOKOUT ROAD, BOULDER CO 80301 |
| Joseph P Lyssikatos |
director, officer: Chief Scientific Officer |
6200 LOOKOUT ROAD, BOULDER CO 80301 |
| Samuel Kintz |
director, officer: President and CEO |
ENLIVEN THERAPEUTICS INC, 6200 LOOKOUT ROAD, BOULDER CO 80301 |
| Richard A. Heyman |
director |
5871 OBERLIN DRIVE, SUITE 150, SAN DIEGO CA 92121 |
| 5am Partners Vi, Llc |
10 percent owner |
501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| Rishi Gupta |
director, 10 percent owner |
C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043 |
| Andrew J. Schwab |
director |
C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| Helen Louise Collins |
director |
TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080 |
| Jake Bauer |
director |
C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080 |
| 5am Opportunities I, L.p. |
10 percent owner |
501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| 5am Opportunities I (gp), Llc |
10 percent owner |
501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| Orbimed Genesis Gp Llc |
10 percent owner |
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
| Kush Parmar |
10 percent owner |
C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| 5am Ventures Vi, L.p. |
10 percent owner |
501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
Enliven Therapeutics (Enliven Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ELVN has been successfully added to your 